×
0 -0.002442748091603 0.0458015267175573 0.0687022900763359 0.144198473282443 0.183206106870229 0.183206106870229 0.225190839694656
Stockreport

Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket [Seeking Alpha]

SAGE THERAPEUTICS (SAGE)  More Company Research Source: Seeking Alpha
Last sage therapeutics earnings: 5/3 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarketSage Therapeutics (NASDAQ:SAGE) is up52% premarket on light volume in response to itsannouncement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.The 89-subject study met its primary endpoint of a statistically significant average reduction in HAM-D score from baseline to day 15 (p8:00 am ET to discuss the results.SAGE-217, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function. The company intends to advance the program into Phase 3 development.See all stocks on the move » [Read more]

IMPACT SNAPSHOT EVENT TIME: SAGE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS